Placebo [clinicaltrials_resource:NCT00912925/group/O1]
Patients in the placebo-control group were administered a solution of 100 mM sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
group [clinicaltrials_vocabulary:group]
NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/300360a87f3717038da12948c4a6e161]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/307694879e7a40670a9146ae43d33272]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/41ecb764fac77497b245b02a547b28cd]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/45c42a31e723f74cd7ec77fb0beff141]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/4b522138b999ae1eb8abf491f23c0a0d]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/4c4d2485076e690ac1bb6328a9c0ec90]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/4da0798d5f8a5638a5b299d21a12d754]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/5e704bfcf75b3e4da34b4ee5ebb5247a]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/63fc7f2976d6304931501819215aea7f]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/709197e99c4445406eb5f63aeebd25b9]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/7b90a37c1567779425da1eeee3900faf]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/7c33bb45b78b298aa4273a2a1775b0fb]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/7f7507fcf819eb432eb0636a96a0bc91]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/8b35ddbfb1e9ec48dc31aaa2cabbf772]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/9ffacb4daa5b5bcb203d4422c7cc5c3b]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/a95b60125204489a9ec90b733caf3a92]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/b21f2e80fd9d6f3d9e7875aaba25729a]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/b902bbc384b514e7765b740f1eeab739]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/bcf47496599e97fb845c6afd3dfdbcea]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/c3e437ed5b656110caa41f43ac1fc4f7]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/c4ba136197d451afc6244f617c1d0b0c]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/ca572b3686a9dbfdcfa1374681b1770d]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/f6a987e403d5a047c42e49767702e14d]NCT00912925 measurement [clinicaltrials_resource:NCT00912925/measurement/f9cc64410b11b0c2d6066f7e0d38aacf]
group id [clinicaltrials_vocabulary:group-id]
Placebo [clinicaltrials_resource:NCT00912925/group/O1]
Patients in the placebo-control group were administered a solution of 100 mM sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
Bio2RDF identifier
NCT00912925/group/O1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00912925/group/O1
group id [clinicaltrials_vocabulary:group-id]
description
Patients in the placebo-contro ...... ours once weekly for 26 weeks.
@en
identifier
clinicaltrials_resource:NCT00912925/group/O1
title
Placebo
@en
type
label
Placebo [clinicaltrials_resource:NCT00912925/group/O1]
@en